Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
This activity is supported by an educational grant from Bristol-Myers Squibb.
Release Date: July 31, 2018
Expiration Date: July 31, 2019
Media: Internet - based
Instructions for This Activity and Receiving Credit
This educational initiative is directed toward medical oncologists, oncology pathologists, clinical/biomedical researchers, hematologists, pathologists, and other healthcare professionals interested in personalized medicine and biomarker research. Nurse practitioners, nurses, physician assistants, pharmacists, fellows, and other healthcare professionals are also invited to participate.
Upon completion of this activity, participants should be better prepared to:
Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Associate Professor, Department of Hematology/Oncology
Co-Director, Immune Monitoring Facility
Lung Cancer and Mesothelioma TRDG Member
Fox Chase Cancer Center
Disclosure: Grant/Research Support: Millennium, Merck, Celgene, Lilly, BMS; Consultant: BMS, Lilly, Genentech, Pfizer, Merck, AstraZeneca, Genmab, Celgene, EMD Serono, Boehringer Ingelheim, Regeneron, BioNTech, Cantargia ABThe staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty member, and do not reflect those of PER® or the company that provided commercial support for this activity.
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Multiple Myeloma
Feb 28, 2019
Feb 28, 2019
Feb 28, 2019
23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
February 28, 2019 - March 3, 2019